Markt geschlossen -
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
870.45 INR | -1.44% |
|
-34.03% | -37.26% |
13.02. | NATCO Pharmas konsolidierter Gewinn sinkt im 3. Quartal des Geschäftsjahres; Aktien brechen um 19% ein | MT |
13.02. | NATCO Pharma strebt eine Akquisition an | CI |
Zu einer Liste hinzufügen 0 ausgewählt | Umsatz (Y-1) | Nettogewinn (Y-1) | EBIT-Marge (Y-1) | ROE (Y-1) | ROA (Y-1) | Verschuldungsgrad (Y-1) | |
---|---|---|---|---|---|---|---|
480 Mio. | 34.72% | 39.13% | 25.88% | - | -0.59x | ||
34.12 Mrd. | 15.36% | 20.68% | 48.93% | 9.23% | 2.6x | ||
88.82 Mrd. | 15.84% | 29.8% | 35.03% | 12.95% | 0.37x | ||
40.31 Mrd. | 34.78% | 44.19% | 80.78% | 25.88% | 0.52x | ||
56.33 Mrd. | 7.59% | 41.43% | 222.49% | 8.62% | 2.45x | ||
66.76 Mrd. | 13.68% | 34.42% | 43.45% | 15.69% | 0.74x | ||
45.81 Mrd. | 13.01% | 31.73% | 29.77% | 11.48% | 1.66x | ||
60.12 Mrd. | 0.61% | 10.33% | 9.18% | 3.56% | 2.77x | ||
50.32 Mrd. | 23.73% | 38.74% | 34.74% | 15.58% | 0.85x | ||
33.42 Mrd. | 12.24% | 44.96% | 177.29% | 11.36% | 2.33x | ||
58.5 Mrd. | 3.62% | 15.9% | 11.37% | 4.96% | 3.8x | ||
42.53 Mrd. | 13.98% | 27.61% | 11.75% | 4.43% | 0.68x | ||
27.12 Mrd. | 20.89% | 38.66% | 38.46% | 13.49% | 1.34x | ||
48.3 Mrd. | 18.53% | 10.77% | 7.93% | 5.22% | 6.98x | ||
7.88 Mrd. | 29.29% | 39.52% | 21.3% | 23.34% | -1.57x | ||
38.63 Mrd. | 16.25% | 28.97% | 52.48% | 10.55% | 1.29x | ||
10.59 Mrd. | 12.53% | 13.21% | 12.8% | 7.95% | -2.01x | ||
14.4 Mrd. | 9.28% | 22.55% | 6.37% | 3.05% | 3.01x | ||
28.19 Mrd. | 3.38% | 5.02% | 2.1% | 0.36% | 4.66x | ||
Durchschnitt | 39.61 Mrd. | percentage-no-prefix | percentage-no-prefix | percentage-no-prefix | percentage-no-prefix | 1.68x | |
Gewichteter Durchschnitt nach Marktkapitalisierung | 48.08 Mrd. | percentage-no-prefix | percentage-no-prefix | percentage-no-prefix | percentage-no-prefix | 1.79x |
- Börse
- Aktien
- A2ABRD Aktie
- Sektor NATCO Pharma Limited
- Finanzielle Vergleiche

MarketScreener is also available in this country: United States.
Switch edition